PharmaCyte Biotech, Inc. (PMCB) stock
PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
$5.37−0.05 (-0.92%)
Close on Nov 18, 2026Market cap $57.65MP/E –Yield –
PharmaCyte Biotech gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
PharmaCyte Biotech's gross profit for the twelve months ending Apr 30, 2017 was $0. For fiscal 2016 it was $0. The highest annual figure on record is $93.89K in fiscal 2011.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2016 | Apr 30, 2016 | $0 | – |
| FY2015 | Apr 30, 2015 | $0 | – |
| FY2014 | Apr 30, 2014 | $0 | -100.0% |
| FY2013 | Apr 30, 2013 | $2.54K | -94.6% |
| FY2012 | Apr 30, 2012 | $47.18K | -49.8% |
| FY2011 | Apr 30, 2011 | $93.89K | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2017CQ1 2017 | Apr 30, 2017 | $0 | – |
| Q3 FY2017CQ4 2016 | Jan 31, 2017 | $0 | – |
| Q2 FY2017CQ3 2016 | Oct 31, 2016 | $0 | – |
| Q1 FY2017CQ2 2016 | Jul 31, 2016 | $0 | – |
See a number that looks wrong?